Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.
Ambagon’s platform approach will open opportunities to address major unmet clinical needs beyond oncology.
Ambagon’s platform approach will open opportunities to address major unmet clinical needs beyond oncology.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $84.91M
Founded date: 2020
Investors 5
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| 09.01.2022 | RA Capital... | racap.com |
| 07.09.2022 | MRL Ventur... | mrlv.com |
| - | Droia Onco... | droiaventu... |
| - | For Good V... | forgoodven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.01.2022 | - | $84.91M | - |
Mentions in press and media 3
| Date | Title | Description |
| 08.01.2022 | US-based biotech startup Ambagon Therapeutics raises USD 85 million in Series A round | Ambagon Therapeutics, a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules, has raised USD 85 million in a Series A funding round led by Nextech Invest on 6 January 2022. |
| 07.01.2022 | Biotech startup Ambagon Therapeutics raises €75.1M from Amsterdam-based Inkef Capital, others | Ambagon Therapeutics is a biotechnology company that is developing cancer molecule therapeutics. The company has offices in San Carlos, California, and Eindhoven, the Netherlands. On Thursday, it announced that it has raised $85M (approx €7... |
| 07.01.2022 | Ambagon Therapeutics Raises $85M in Series A Funding | Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding. The round was led by Nextech Invest with participation from RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ve... |